Immunogenic Cell Death Role in Urothelial Cancer Therapy
/in Immunogenic Cell Death, International Publications, Newcastle Disease Virus, Urothelial CarcinomaImmune escape mechanisms and immunotherapy of urothelial bladder cancer
/in Dendritic Cells, International Publications, Urothelial CarcinomaCancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities
/in Dendritic Cells, International Publications, Prostate Cancer, Urothelial CarcinomaPersistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes
/in International Publications, Newcastle Disease Virus, Urothelial CarcinomaCell Therapies in Bladder Cancer Management
/in Dendritic Cells, International Publications, Urothelial CarcinomaNovel immunotherapy combinations for genitourinary cancers
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial CarcinomaPreliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
/in Dendritic Cells, Urothelial CarcinomaVaccination of Urological Cancer Patients With WT1 Peptide-Pulsed Dendritic Cells in Combination With Molecular Targeted Therapy or Conventional Chemotherapy Induces Immunological and Clinical Responses
/in Dendritic Cells, Hypernephroma, International Publications, Urothelial CarcinomaCurrent and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial Carcinoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- The Complexity of Malignant Glioma Treatment
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature